guanosin
analogu
readili
convert
allyl
deriv
upon
diazot
tbuono
tmsn
yield
azido
deriv
previous
analyz
solventdepend
equilibrium
azidopurin
nucleosid
contrast
allyl
azido
nucleosid
appear
exist
predominantli
azido
form
rel
independ
solvent
polar
present
describ
case
tetrazol
appear
minor
consist
presenc
azido
function
neat
azid
display
promin
ir
band
cm
screen
condit
ligat
azido
nucleosid
alkyn
show
cucl
tbuoh
h
optim
yield
nucleosid
yield
remov
silyl
group
et
follow
deallyl
phso
napd
pph
gave
triazolylinosin
nucleosid
continu
demonstr
versatil
purin
nucleosid
one
triazolylinosin
deriv
convert
two
adenosin
analogu
via
intermedi
mild
condit
product
desilyl
biolog
assay
two
triazolyl
adenosin
analogu
demonstr
pronounc
antiprolif
activ
human
ovarian
colorect
carcinoma
cell
cultur
evalu
antivir
activ
broad
spectrum
dna
rna
virus
triazolylinosin
deriv
show
modest
inhibitori
activ
cytomegaloviru
cucatalyz
version
classic
huisgen
azidealkyn
cycloaddit
highli
atomeconom
reaction
often
requir
mild
condit
factor
render
cucatalyz
azidealkyn
cycloaddit
cuaac
highli
attract
modif
complex
sensit
molecul
nucleosid
recent
report
facil
gener
synthesi
azidopurin
nucleosid
use
cuaac
reaction
new
compound
show
low
cytostat
activ
ovarian
carcinoma
cell
line
gener
azidealkyn
cycloaddit
reaction
highli
import
transform
chemistri
nucleosid
dna
knowledg
previou
report
cuaac
reaction
nucleosid
first
describ
reaction
posit
purin
nucleosid
hand
cuaac
chemistri
involv
azidopurin
nucleosid
report
context
adenosin
receptor
research
well
develop
antituberculosi
agent
describ
reaction
analogu
gener
three
method
synthesi
adenosin
deriv
first
involv
treatment
ribofuranosylpurin
nitrou
acid
second
cucatalyz
azid
triosilyl
ribofuranosylpurin
third
involv
diazotizationazid
trioacetyl
isoamylonoazidotrimethylsilan
tmsn
follow
replac
chlorid
amino
group
current
studi
interest
cuaac
reaction
analogu
synthes
deriv
less
well
develop
comparison
adenosin
analogu
reaction
acid
nan
shown
yield
subsequ
convert
reaction
acid
phosphatas
similarli
requir
rel
nontrivi
synthesi
convert
deriv
within
context
dna
oligom
purpos
need
simpl
gener
access
paper
report
synthesi
suitabl
protect
deriv
applic
toward
cuaac
reaction
evalu
anticanc
antivir
properti
inosin
analogu
appropri
deprotect
protocol
also
report
methodolog
convers
triazolylinosin
deriv
adenosin
analogu
via
deriv
well
develop
doubli
reactiv
purin
ribonucleosid
recent
report
inosin
guanosin
deriv
well
correspond
analogu
except
effect
reagent
introduct
substitu
posit
purin
nucleosid
basi
result
reason
allylguanosin
would
excel
precursor
present
work
previous
develop
synthesi
tertbutyldimethylsilyl
precursor
report
acid
potenti
use
gener
deriv
despit
shown
scheme
expediti
directli
instal
azido
group
posit
diazot
amino
group
presenc
tmsn
silylprotect
analogu
could
synthes
via
procedur
ca
yield
azido
deriv
purin
purin
nucleosid
exist
equilibrium
two
possibl
tetrazolyl
isom
similarli
b
exist
two
tautom
term
b
b
depend
upon
nitrogen
atom
purin
involv
among
two
azid
deriv
synthesi
triflat
report
yield
compound
report
display
tetrazol
tautom
case
assess
h
nmr
indic
exist
predominantli
azid
cdcl
aceton
dmsod
consist
ir
spectra
show
absorpt
cm
respect
comparison
deriv
demonstr
tetrazolyl
isom
apart
factor
temperatur
solvent
polar
electron
natur
substitu
also
influenc
azidetetrazol
ratio
purinyl
deriv
wherea
electrondon
substitu
favor
ringclos
tetrazolyl
form
azid
form
prefer
electronwithdraw
group
significantli
greater
proport
azido
rather
tetrazolyl
form
deriv
b
compar
possibl
link
substitu
effect
two
tetrazolyl
form
form
gener
invok
nucleosid
synthesi
azido
deriv
b
complet
condit
effectu
ligat
reaction
alkyn
evalu
tabl
previou
work
nucleosid
observ
reduct
azid
amin
compet
process
biphas
condit
essenti
order
obtain
satisfactori
azidealkyn
ligat
interestingli
applic
condit
result
unsatisfactori
outcom
entri
switch
solvent
tbuohh
gave
improv
result
entri
cu
catalyst
gave
modest
improv
entri
wherea
cucl
prove
best
condit
test
afford
product
yield
entri
therefor
gener
azidealkyn
ligat
chemistri
next
investig
use
ribos
deriv
well
analogu
result
experi
summar
tabl
seri
protect
triazolylinosin
deriv
avail
deprotect
product
becam
focu
two
possibl
sequenc
could
envis
either
deprotect
allyl
group
follow
desilyl
vice
versa
desilyl
et
follow
deallyl
prefer
order
note
nucleosid
desilyl
complex
leav
fluorid
contamin
instanc
difficult
elimin
henc
chosen
deprotect
sequenc
offer
possibl
chromatograph
purifi
product
desilyl
prior
deallyl
also
gener
recommend
check
product
desilyl
f
nmr
sever
condit
test
purpos
pd
dba
binap
morpholin
thf
pd
dba
binap
et
nh
hco
ch
cl
pd
pph
sodium
benzenesulfin
phso
na
thf
first
two
set
condit
success
use
pd
pph
phso
na
prove
optim
scheme
show
product
prepar
deprotect
synthes
seri
triazolylinosin
analogu
also
consid
modifi
guanin
nucleosid
virtu
nitrogen
atom
consid
methodolog
facil
synthesi
triazolyladenosin
analogu
deriv
nucleosid
purpos
previous
describ
methodolog
activ
amid
linkag
via
deriv
appear
reason
approach
shown
scheme
deallyl
follow
exposur
result
silylprotect
triazolylinosin
deriv
dimethylamino
phosphonium
hexafluorophosph
bop
ipr
net
thf
room
temperatur
led
format
correspond
benzotriazolyl
deriv
yield
reaction
morpholin
benzyl
amin
conduct
dme
yield
adenosin
deriv
yield
respect
product
desilyl
yield
triazolyl
adenosin
analogu
forego
experi
clearli
show
azidealkyn
ligat
could
effect
util
synthes
triazolyl
nucleosid
analogu
combin
chemistri
lead
purin
nucleosid
produc
power
new
approach
difunction
purin
scaffold
point
consid
whether
appropri
function
doubli
reactiv
purin
nucleosid
deriv
could
obtain
therefor
synthesi
purin
nucleosid
deriv
investig
would
allow
us
evalu
stabil
benzotriazolyl
moieti
diazotizationazid
condit
also
provid
rout
novel
reactiv
nucleosid
difunction
posit
purin
context
hydroxylprotect
benzotriazolyl
guanosin
deriv
convert
halo
f
cl
purin
nucleosid
chose
diazot
tertbutyldimethylsilyl
guanosin
tbuono
tmsn
scheme
along
line
previous
publish
method
reaction
gave
unoptim
yield
indic
gener
stabil
group
reaction
condit
h
c
nmr
spectra
cdcl
show
presenc
three
isom
presum
azid
two
tetrazolyl
form
exampl
three
singlet
observ
h
nmr
spectrum
ppm
correspond
purinyl
reson
although
two
reson
observ
ppm
hmqc
spectrum
clearli
show
three
reson
ppm
three
reson
ppm
ppm
use
determin
isom
ratio
time
attempt
made
assign
structur
isom
ir
spectrum
show
absorpt
cm
doubli
reactiv
compound
two
preinstal
reactiv
entiti
potenti
function
cuaac
n
ar
chemistri
respect
work
along
line
forthcom
compound
evalu
antivir
activ
broad
varieti
dna
rna
virus
sever
compound
ie
see
tabl
show
margin
activ
cytomegaloviru
cmv
wherea
anticmv
activ
somewhat
pronounc
inde
inosin
deriv
show
activ
cmv
human
embryon
lung
hel
cell
ec
none
compound
show
antivir
activ
virus
subtox
concentr
except
inosin
deriv
endow
moder
antivesicular
stomat
viru
vsv
activ
human
cervix
carcinoma
hela
cell
cultur
activ
could
confirm
human
embryon
lung
hel
fibroblast
cell
cultur
viru
make
moder
activ
rather
celltyp
specif
yet
hela
hel
cell
cultur
toxic
observ
may
also
mean
antivsv
activ
notic
vsvhela
cell
assay
due
underli
toxic
host
cell
rather
specif
antivir
activ
compound
antivir
assay
system
perform
compound
highest
impact
mammalian
cell
morpholog
highli
depend
natur
cell
line
use
viru
host
minimum
detect
morphologyalt
cytotox
concentr
mcc
canin
kidney
mdck
hela
felin
kidney
crfk
green
monkey
kidney
vero
hela
cell
inosin
deriv
deriv
also
evalu
cytostat
activ
murin
leukemia
human
lymphocyt
cem
hela
cell
modest
cytostat
activ
notic
sever
compound
particular
hela
cell
usual
somewhat
sensit
inhibitori
potenti
compound
cell
line
also
ribos
deriv
consist
cytostat
correspond
deriv
among
compound
test
prove
cytostat
irrespect
natur
tumor
cell
line
ic
adenosin
deriv
poorli
cytostat
ic
newli
synthes
triazolyl
nucleosid
analogu
also
test
antiprolif
activ
use
human
ovarian
cancer
cell
paclitaxelresist
clone
colorect
carcinoma
cell
clone
tabl
sever
compound
modestli
activ
inact
adenosin
deriv
show
best
activ
among
two
bear
morpholinyl
group
activ
inosin
deriv
phthalimido
triazolyl
substitu
also
show
activ
show
notabl
activ
compound
also
activ
knockout
cell
albeit
higher
concentr
seri
adenosin
deriv
emerg
interest
cytostat
candid
show
activ
knockout
cell
paper
describ
synthes
deriv
use
cuaac
reaction
contrast
azidopurin
nucleosid
azid
exhibit
signific
equilibrium
azido
form
appear
predomin
comparison
azidoadenosin
analogu
show
greater
proport
tetrazolyl
form
possibl
link
greater
electronwithdraw
allyloxi
group
posit
present
case
product
cuaac
reaction
desilyl
evalu
potenti
antivir
activ
unfortun
none
compound
prove
antivir
activ
subtox
concentr
except
compound
endow
moder
inhibitori
activ
vesicular
stomat
viru
compound
show
activ
cytomegaloviru
howev
current
unclear
whether
antivsv
activ
specif
antivir
effect
due
underli
compound
toxic
triazolylinosin
nucleosid
consid
modifi
guanin
analogu
also
convert
deriv
n
ar
substitut
benzotriazolyloxi
group
amin
furnish
triazolyl
adenosin
analogu
addit
convert
silylprotect
guanosin
doubli
reactiv
purin
nucleosid
deriv
interestingli
base
upon
nmr
result
compound
appear
exist
azid
two
tetrazolyl
isom
nucleosid
deriv
react
via
cuaac
via
n
ar
find
broad
util
greatli
diversifi
purin
nucleosid
scaffold
via
gener
simpl
oper
procedur
thin
layer
chromatographi
perform
silica
plate
column
chromatograph
purif
perform
mesh
silica
gel
ch
cl
distil
cacl
thf
distil
lialh
na
prior
use
reagent
obtain
commerci
sourc
use
receiv
h
nmr
spectra
record
mhz
solvent
indic
referenc
residu
proton
solvent
reson
c
nmr
data
record
mhz
solvent
indic
referenc
solvent
reson
case
hrm
analys
esi
ioniz
tof
analyz
use
although
report
literatur
larger
scale
synthes
describ
ad
dropwis
follow
addit
tetbuono
ml
mmol
reaction
mixtur
stir
h
brought
room
temperatur
allow
stir
h
reaction
mixtur
dilut
meoh
h
allow
stir
h
extract
ch
cl
ml
organ
layer
wash
water
brine
evapor
solvent
follow
chromatograph
purif
silica
gel
column
use
aceton
hexan
afford
g
yield
thick
paleyellow
oil
r
f
tabl
reaction
time
reaction
mixtur
dilut
ch
cl
wash
water
follow
brine
organ
layer
dri
na
concentr
reduc
pressur
chromatograph
purif
silica
gel
column
use
etoac
hexan
afford
mg
yield
offwhit
foam
r
f
sio
etoac
hexan
sich
step
desilyl
et
mmol
ad
solut
mg
mmol
dri
thf
ml
reaction
mixtur
stir
room
temperatur
h
mixtur
evapor
stream
nitrogen
ga
use
polypropylen
pipet
crude
product
purifi
chromatographi
silica
gel
column
use
meoh
etoac
give
step
desilyl
use
procedur
describ
desilyl
compound
synthes
mg
mmol
et
step
desilyl
step
desilyl
use
procedur
describ
desilyl
compound
synthes
mg
mmol
et
step
desilyl
use
procedur
describ
desilyl
compound
synthes
mg
mmol
et
mmol
step
desilyl
use
procedur
describ
desilyl
step
deallyl
desilyl
product
mg
mmol
obtain
step
deallyl
describ
use
pd
pph
mg
mol
step
desilyl
use
procedur
describ
desilyl
step
desilyl
use
procedur
describ
desilyl
step
deallyl
desilyl
product
mg
mmol
obtain
step
deallyl
describ
use
pd
pph
mg
mol
phso
na
step
desilyl
use
procedur
describ
desilyl
step
desilyl
step
desilyl
step
desilyl
step
clean
dri
reaction
vial
equip
stir
bar
place
mg
mmol
dri
dme
ml
morpholin
mmol
ad
reaction
mixtur
flush
nitrogen
ga
allow
stir
room
temperatur
h
reaction
mixtur
evapor
residu
dissolv
etoac
wash
water
contain
small
amount
nacl
aqueou
layer
separ
reextract
etoac
combin
organ
layer
dri
na
evapor
dryness
chromatograph
purif
crude
materi
silica
gel
column
use
etoac
hexan
afford
mg
yield
white
foam
r
f
sio
etoac
hexan
cytostat
effect
test
compound
murin
leukemia
cell
human
tlymphocyt
cell
cem
human
cervix
carcinoma
cell
hela
evalu
follow
appropri
number
cell
suspend
growth
medium
allow
prolifer
plate
presenc
variabl
amount
test
compound
humidifi
co
control
atmospher
h
h
cem
h
hela
number
cell
count
coulter
counter
ic
valu
defin
concentr
requir
inhibit
cell
prolifer
methodolog
antihiv
assay
follow
human
cem
cellsml
cell
infect
ccid
hiv
iii
b
rod
ml
seed
well
microtit
plate
contain
appropri
dilut
test
compound
day
incub
hivinduc
cem
giant
cell
format
examin
microscop
effect
concentr
ec
defin
compound
concentr
requir
inhibit
syncytia
format
cytostat
concentr
cc
defin
compound
concentr
requir
inhibit
cem
cell
prolifer
comparison
mockinfect
cell
cultur
determin
gi
use
ovarian
cancer
colon
carcinoma
cell
line
essenti
describ
mm
stock
solut
paclitaxel
ptx
obtain
drug
synthesi
branch
nation
cancer
institut
prepar
dmso
control
sampl
contain
vv
dmso
vehicl
level
equival
drugtreat
cultur
ovarian
cancer
cell
cultur
rpmi
medium
without
phenol
red
contain
fetal
bovin
serum
humidifi
carbon
dioxid
incub
cell
maintain
presenc
ngml
ptx
verapamil
medium
replac
regular
medium
two
three
day
plate
cell
well
plate
cell
line
maintain
mccoy
medium
fetal
bovin
serum
cell
plate
tissu
cultur
plate
h
compound
prepar
dmso
stock
solut
ad
quadrupl
least
five
differ
concentr
test
compound
experi
one
plate
consist
entir
cell
medium
use
time
zero
cell
number
determin
timeday
addit
compound
four
day
promega
cell
titer
reagent
ad
well
plate
incub
tissu
cultur
incub
approxim
h
later
plate
read
use
plate
reader
nm
minu
nm
absorb
wavelength
data
analyz
use
excel
spreadsheet
grid
result
averag
valu
rang
cell
cultur
expans
two
concentr
use
calcul
gi
b
yield
isol
purifi
product
